$15.80+0.29 (+1.87%)
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases.
BioAge Labs, Inc. in the Healthcare sector is trading at $15.80 with a market capitalization of $713M. Wall Street consensus targets $49.50 (8 analysts), implying a +213.3% move over the next 12 months. The stock is currently 34% below its 52-week high of $24.00, remaining 17.0% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets that allows users to identify targets based on insights...
BioAge Labs (NASDAQ:BIOA) executives used a fireside chat at the Jefferies 2026 Global Healthcare Conference to outline the company’s plans for BGE-102, its lead NLRP3 inhibitor, with near-term readouts expected in cardiovascular risk and diabetic macular edema. The company’s chief business officer
We recently compiled a list of the 8 Best Small Cap Pharma Stocks to Buy Right Now. BioAge Labs, Inc. (NASDAQ:BIOA) is one of the best small cap pharma stocks to buy right now. TheFly reported on May 13 that BIOA received newly initiated coverage with a Buy rating and a $40 price target by […]
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Keefe, Bruyette & Woods analyst Alex Bond initiated coverage on Coinshares PLC (NASDAQ:CSHR) with an Outperform rating and announces Price Target of $9. CoinShares shares closed at $6.11 on Tuesday. See how other analysts view this stock. BTIG analyst Thomas Shrader initiated coverage on BIOAGE L
AMD, Under Armour downgraded: Wall Street's top analyst calls
BioAge Labs, Inc. ( NASDAQ:BIOA ) investors will be delighted, with the company turning in some strong numbers with its...